Cell function and viability in glucose polymer peritoneal dialysis fluids.
OBJECTIVE
To investigate the biocompatibility profile of a new peritoneal dialysis fluid containing glucose polymer (GPF).


METHODS
Viability and function of peripheral neutrophils (PMN) from healthy donors and cultured human peritoneal mesothelial cells were assessed in vitro after exposure to dialysis fluids. Phagocytosis, leukotriene B4 synthesis, and respiratory burst activation were measured following stimulation with serum-treated zymosan (STZ) or opsonized Staphylococcus epidermidis (S. epidermidis). Bacterial growth in the fluids was also investigated. In vivo pH equilibration of GPF and subsequent respiratory burst activation following incubation in spent dialysate were studied.


RESULTS
For all the host defense parameters measured, commercial dialysis fluids (Dianeal; 1.36% and 3.86% glucose) and GPF (pH 5.2) were significantly more inhibitory than the control buffer (pH 7.3). Mesothelial cell viability was reduced by all the fluids tested irrespective of pH. Glucose polymer fluid was significantly more inhibitory than Dianeal 1.36% for STZ phagocytosis and respiratory burst activation. In contrast, it was less suppressive than Dianeal 3.86% for LTB4 synthesis. For all parameters tested, except LTB4 generation, there was a marked effect of pH, with GPF being significantly more inhibitory at pH 5.2 than at pH 7.3. None of the fluids tested supported the growth of S. epidermidis, although the viable counts in GFP were significantly higher than in Dianeal. Fluid inhibition of PMN respiratory burst activation and cytotoxicity were reduced in a time-dependent manner following increasing dwell time in vivo.


CONCLUSIONS
GPF does not appear to be significantly different from Dianeal as far as host defense parameters are concerned. However, the cell viability and bacterial survival data suggest some possibly negative aspects of this fluid formation.
Institute of Nephrology, University of Wales College of Medicine, Cardiff Royal Infirmary, United Kingdom.
T
T
Liberek
N
N
Topley
C D
CD
Mistry
G A
GA
Coles
T
T
Morgan
R A
RA
Quirk
J D
JD
Williams
D001672:Biocompatible Materials; D002470:Cell Survival / Q000187:drug effects; D002478:Cells, Cultured; D015169:Colony Count, Microbial; D015314:Dialysis Solutions / Q000494:pharmacology*; D004848:Epithelium / Q000187:drug effects / Q000502:physiology; D005936:Glucans / Q000494:pharmacology*; D006801:Humans; D066298:In Vitro Techniques; D007770:L-Lactate Dehydrogenase / Q000378:metabolism; D007963:Leukocytes, Mononuclear / Q000187:drug effects / Q000502:physiology; D007975:Leukotriene B4 / Q000096:biosynthesis; D008163:Luminescent Measurements; D010530:Peritoneal Dialysis; D010587:Phagocytosis / Q000187:drug effects; D013212:Staphylococcus epidermidis / Q000187:drug effects / Q000254:growth & development
D001672:Biocompatible Materials; D015314:Dialysis Solutions; D005936:Glucans; D007975:Leukotriene B4; D007770:L-Lactate Dehydrogenase